Insights about U.S. Stocks that landed in the Green-Zone during Wednesday’s trade, are depicted underneath:
KaloBios Pharmaceuticals Inc (NASDAQ:KBIO)’s shares picked up 7.86%, and closed at $0.755. The company holds the market capitalization of 22.07M. The stock return on equity value is - 82.60%, while return on assets value is -59.80%. Its 20-day moving average gained 63.60%, and the stock moved below 50-day moving average of -0.50%. The mean recommendation of analysts for this stock is 2.00.(where 1=Buy, 5=Sale).
Hemispherx BioPharma, Inc (NYSEMKT:HEB), raised 7.76%, and closed at $0.268.
Hemispherx Biopharma, Inc. (HEB), declared that its manufacturing site located in New Brunswick, New Jersey, presently configured at over 43,000 square feet, has accomplished its $8 million of upgrades. These upgrades will provide for a higher capacity, more cost effective manufacturing process for the production of Alferon N Injection(R), the only FDA-approved natural alpha interferon. The added efficiency of the process has been accomplished by integrating continuous flow manufacturing technology throughout the process. This has led to improved cost efficiency, improved yields, real-time process monitoring, flexibility to tailor batch size for lean manufacturing, and improved operational safety as seen in other cutting edge pharmaceutical companies.
The upgraded facility is installed with a 600-liter bioreactor instead of a labor-intensive method using 100 x 6 liter flasks for the same size batch. Scaling up to the automated 600-liter bioreactor has eliminated ~ 80% of the manpower formerly needed for this part of the process.
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical corporation engaged in the manufacture and clinical development of new drug entities (“biological modifiers”) for treatment of seriously debilitating disorders especially life-threatening viruses. Hemispherx’s flagship products comprise Alferon(R) N Injection(R) and the experimental therapeutics Ampligen(R) and Alferon(R) LDO.
Intercept Pharmaceuticals Inc (NASDAQ:ICPT), enhanced 7.73%, and closed at $266.49.
Intercept Pharmaceuticals, Inc. (ICPT), a clinical stage biopharmaceutical corporation focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, stated financial results for the fourth quarter and full year ended December 31, 2014.
2014 Full-Year Financial Results:
As of December 31, 2014, Intercept’s cash, cash equivalents and investment securities accessible for sale totaled about $239.7 million, contrast to $144.8 million at December 31, 2013. The net $94.9 million raise is primarily due to the net proceeds of $183.5 million from a public equity offering in April 2014 offset by $87.7 million in cash outflows from operations.
In February 2015, Intercept accomplished an underwritten public offering of 1,150,000 shares of ordinary stock. All shares in the offering were sold by Intercept at a public offering price of $176.00 per share. Intercept estimates that net proceeds were about $191.2 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Net loss attributable to ordinary stockholders for the full year 2014 was $283.2 million, or $13.63 per share, contrast to a net loss of $67.8 million, or $3.76 per share, for the full year 2013, representing a raise of $215.4 million, or $9.87 per share. The 2014 net loss comprises $170.8 million of non-cash warrant revaluation expense, an raise of $142.4 million from 2013, and $20.1 million in non-cash stock-based compensation expense, an raise of $10.7 million from 2013.
Intercept is a biopharmaceutical corporation focused on the development and commercialization of novel therapeutics to treat neglected chronic liver diseases utilizing its expertise in bile acid chemistry. The corporation’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases, counting primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia.
American Eagle Outfitters (NYSE:AEO), enhanced 7.69%, and closed at $15.96, hitting new 52-week high of $16.36.
American Eagle Outfitters, Inc. (AEO), declared a quarterly cash dividend of $0.125 per share, marking the corporation’s 43rd successive quarterly dividend. The $0.125 dividend was declared on March 4, 2015 and is payable on April 22, 2015 to stockholders of record at the close of business on April 8, 2015.
American Eagle Outfitters, Inc. (AEO) is a leading global specialty retailer offering high-quality, on-trend clothing, accessories and personal care products at affordable prices under its American Eagle Outfitters® and Aerie® brands.
